• 1
    Burnier M. Blood pressure control and implementation of guidelines in clinical practice: can we fill the gap? J Hypertens. 2002;20:12511253.
  • 2
    Barrios V, Escobar C, Calderón A, et al. Blood pressure and lipid goal attainment in the hypertensive population in the primary care setting in Spain. J Clin Hypertens (Greenwich). 2007;9:324329.
  • 3
    Barrios V, Banegas JR, Ruilope LM, et al. Evolution of blood pressure control in Spain. J Hypertens. 2007;25:19751977.
  • 4
    Llisterri Caro JL, Rodríguez Roca GC, Alonso Moreno JF, et al. Blood pressure control in Spanish hypertensive patients in primary health care centres. PRESCAP 2002 study. Med Clin (Barc). 2004;122:165171.
  • 5
    Llisterri Caro JL, Rodríguez Roca GC, Alonso Moreno JF, et al. Control of blood pressure in Spanish hypertensive population attended in primary health-care. PRESCAP 2006 study. Med Clin (Barc). 2008;130:681687.
  • 6
    Márquez-Contreras E, De Rivas Otero B, Divisón Garrote JA, et al. Are hypertensive patients managed in primary care well evaluated and controlled? HICAP Study [in Spanish] An Med Interna. 2007;24:312316.
  • 7
    Stewart S, MacIntyre K, Capewell S, et al. Heart failure and the aging population: an increasing burden in the 21st century? Heart. 2003;89:4953.
  • 8
    Young JB. The global epidemiology of heart failure. Med Clin North Am 2004;88:11351143.
  • 9
    Rodriguez-Artalejo F, Banegas Banegas JR, Guallar-Castillón P. Epidemiology of heart failure. Rev Esp Cardiolo. 2004;57:163170.
  • 10
    Archana R, Gray D. The quality of life in chronic-disease-heart failure is as bad as it gets. Eur Heart J. 2002;23:18061808.
  • 11
    De Rivas B, Permanyer-Miralda G, Brotons C, et al. Health-related quality of life in unselected outpatients with heart failure across Spain in two different health care levels. Magnitude and determinants of impairment: the INCA study. Qual Life Res. 2008;17:12291238.
  • 12
    Lloyd-Jones DM, Larson MG, Leip EP, et al. Lifetime risk for developing congestive heart failure. The Framingham Heart Study. Circulation. 2002;106:30683072.
  • 13
    Moser M, Hebert PR. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol. 1996;27:12141218.
  • 14
    Kannel WB, D’Agostino RB, Silbershatz H, et al. Profile for estimating risk of heart failure. Arch Intern Med. 1999;159:11971204.
  • 15
    De Rivas B, Divisón JA, Sobreviela E, et al. Prevalence and risk of developing heart failure in hypertensive patients managed in Spanish primary care centres. HICAP study. Rev Clin Esp. 2008;208:513516.
  • 16
    Fahey T, Schroeder K, Ebrahim S. Interventions used to improve control of blood pressure in patients with hypertension. Cochrane Database Syst Rev. 2006; (4):CD005182.
  • 17
    Gómez-Marcos MA, García-Ortiz L, González-Elena LJ, et al. Effectiveness of a quality improvement intervention in blood pressure control in primary care. Rev Clin Esp. 2006;206:428434.
  • 18
    Hunt SA; American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 2005;46 (6):e1e82.
  • 19
    European Society of Hypertension-European Society of Cardiology Guidelines Committee. European Society of Hypertension-European Society of Cardiology guidelines for management of arterial hypertension. J Hypertens. 2003;21:10111053.
  • 20
    Global guidelines for type 2 diabetes. International Diabetes Federation 2005. Disponible en:
  • 21
    American Diabetes Association. Standards of medical care in diabetes--2008. Diabetes Care. 2008;31(suppl 1):S12S54.
  • 22
    Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:24862497.
  • 23
    Barrios V, Escobar C, Calderón A, et al. Cardiovascular risk profile and risk stratification of the hypertensive population attended by general practitioners and specialists in Spain. The CONTROLRISK study. J Hum Hypertens. 2007;21:479485.
  • 24
    Luque M, De Rivas B, Alvarez B, et al. Influence of target organ lesion detection (assessment of microalbuminuria and echocardiogram) in cardiovascular risk stratification and treatment of untreated hypertensive patients. J Hum Hypertens. 2006;20:187192.
  • 25
    Viazzi F, Parodi D, Leoncini G, et al. Optimizing global risk evaluation in primary hypertension: the role of microalbuminuria and cardiovascular ultrasonography. J Hypertens. 2004;22 (5):907913.
  • 26
    Cerasola G, Mulè G, Nardi E, et al. Usefulness of microalbuminuria in cardiovascular risk stratification of essential hypertensive patients. Nephron Clin Pract. 2004;96:123130.
  • 27
    Martínez AM, Sancho T, Armada E, et al. Prevalence of left ventricular hypertrophy in patients with mild hypertension in primary care: impact of echocardiography on cardiovascular risk stratification. Am J Hypertens. 2003;16:556563.